Cogent | Jotup

Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor

Retrieved on:

Tuesday, April 9, 2024

Brain, Disease, CNS, Mouse, Neoplasm, IND, AACR, HER2, Poster, Annual general meeting, Cogent, Pharmaceutical industry

and BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced new preclinical data from the Company’s potent, selective, CNS-penetrant ErbB2 inhibitor program.

Key Points:

and BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced new preclinical data from the Company’s potent, selective, CNS-penetrant ErbB2 inhibitor program.
The data are being presented in a poster session at the American Association for Cancer Research (AACR) 2024 Annual Meeting taking place in San Diego, California.
“These data further demonstrate Cogent’s capability to discover and advance potential best-in-class novel therapies for rare disease populations with high unmet medical need.
Cogent is developing a potential best-in-class EGFR-sparing, brain-penetrant ErbB2 inhibitor that includes potent coverage of key mutations (YVMA, S310F, V842I, L755S) inadequately addressed by currently approved therapies.

Skkynet Reaches Record Sales Growth in First Quarter

Retrieved on:

Monday, March 18, 2024

Cloud, Microsoft, ETK, Microsoft Azure, Industrial, VPN, Cogent

MISSISSAUGA, ON, March 18, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Skkynet Cloud Systems, Inc. (“Skkynet” or “the Company”) (OTCQB: SKKY) is pleased to announce its quarter-end operating and financial results for the period ended January 31, 2023. The Company reported a record first quarter revenue of $630,536 compared to $492,119 for the same period in 2023, a 28% year over year revenue growth. Comprehensive income from operations for the 3-month period was $23,951 compared to a loss of $144,627 for the same period in 2023 due to increased sales.

Key Points:

The Company reported a record first quarter revenue of $630,536 compared to $492,119 for the same period in 2023, a 28% year over year revenue growth.
Comprehensive income from operations for the 3-month period was $23,951 compared to a loss of $144,627 for the same period in 2023 due to increased sales.
“Skkynet’s growing sales and expanding channels have maintained the Company’s upward growth trend.
We had a very successful quarter in elevating our marketing presence, attracting new partners, and maintaining our strong cash position,” stated Andrew Thomas, CEO.

AgreeYa Solutions Celebrates 25 Years of Excellence

Retrieved on:

Tuesday, March 26, 2024

AgreeYa Solutions , a global leader in software, solutions and services, is celebrating a remarkable 25 years of industry success.

Key Points:

AgreeYa Solutions , a global leader in software, solutions and services, is celebrating a remarkable 25 years of industry success.
“AgreeYa’s remarkable 25-year journey stands as a testament to its unwavering commitment to client success,” said managing partner Ajay Kaul.
“Throughout our history, we've prioritized our clients' needs—driving innovation and delivering excellence in every project.
Apart from building solutions that have transformed the lives of communities it serves and protected the environment, AgreeYa also believes in giving back to communities and the environment through its various CSR activities.

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Retrieved on:

Monday, February 26, 2024

HER2, PFS, AAAAI, KIT, Research, Completeness, TSS, ASCO, ASH, WT, Cash, Part, Safety, PEAK, AACR, Cogent, Conference, GIST, Society, PPR, Patient, The, PIPE, FGFR2, Clinical trial, Poster, G&A, Sunitinib, Initiate, IND, Brain, TKI, APEX, Cancer, American Academy, Pharmaceutical industry

WALTHAM, Mass. and BOULDER, Colo., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today provided a business update and reported financial results for the fourth quarter and full year of 2023.

Key Points:

and BOULDER, Colo., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today provided a business update and reported financial results for the fourth quarter and full year of 2023.
SUMMIT is a registration-directed, randomized, double-blind, placebo-controlled, global, multicenter, clinical trial of bezuclastinib in patients with nonadvanced systemic mastocytosis (NonAdvSM).
Cash and Cash Equivalents: As of December 31, 2023, Cogent had cash, cash equivalents and marketable securities of $273.2 million.
During the quarter Cogent also completed and paid for bulk manufacturing campaigns of bezuclastinib to continue supporting the company’s clinical trials.

Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis

Retrieved on:

Thursday, February 22, 2024

Poster, AAAAI, PD, KIT, Week, TSS, ISM, Safety, Quality of life, News, SSM, Overalls, Edema, Cogent, GIST, Deficit spending, Webcast, Mast cell, Patient, SAE, 1B, APEX, American Academy, Pharmaceutical industry

WALTHAM, Mass. and BOULDER, Colo., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today reported positive Part 1b data from the Company’s ongoing SUMMIT trial evaluating bezuclastinib in patients with nonadvanced systemic mastocytosis (NonAdvSM) at the 2024 American Academy of Allergy Asthma & Immunology Annual Meeting (AAAAI) meeting taking place February 23-26, 2024 in Washington, D.C.

Key Points:

“The magnitude and speed of symptomatic reductions, along with corresponding improvements in quality-of-life, reported by patients in SUMMIT Part 1b has not been seen previously with other treatment options in this patient population.
Thirty-four patients in Part 1b were treated with either bezuclastinib or placebo plus best supportive care.
Patients were enrolled with the following sub-types: 33 patients with indolent systemic mastocytosis (ISM) and one patient with smoldering systemic mastocytosis (SSM).
Thirty-four patients enrolled in SUMMIT Part 1b were evaluated for signs of clinical activity over 12 weeks, including well-accepted biomarkers of disease burden.

Cogent Communications to Host Fourth Quarter and Full Year 2023 Earnings Call on February 29, 2024

Retrieved on:

Wednesday, February 7, 2024

Cogent

WASHINGTON, Feb. 7, 2024 /PRNewswire/ -- Cogent Communications Holdings, Inc. ("Cogent") (NASDAQ: CCOI) will host a conference call at 8:30 a.m. (ET) on February 29, 2024 to present Cogent's operating results for the fourth quarter and full year of 2023 and answer questions.

Key Points:

WASHINGTON, Feb. 7, 2024 /PRNewswire/ -- Cogent Communications Holdings, Inc. ("Cogent") (NASDAQ: CCOI) will host a conference call at 8:30 a.m. (ET) on February 29, 2024 to present Cogent's operating results for the fourth quarter and full year of 2023 and answer questions.
Cogent will issue a press release announcing the operating results at 7:00 a.m. (ET) on February 29, 2024.
Participation is open to all parties and this call may be accessed as follows:

Model Portfolio Growth Plateaus as Advisors Pivot to Boost Separately Managed Accounts

Retrieved on:

Tuesday, February 6, 2024

Investment, Education, Spinal muscular atrophies, Growth, Cogent, SMA, Financial adviser

Instead, as advisors seek to align their investment strategies with the expectations of more-affluent clients, they plan to boost allocations to separately managed accounts (SMAs).

Key Points:

Instead, as advisors seek to align their investment strategies with the expectations of more-affluent clients, they plan to boost allocations to separately managed accounts (SMAs).
Just one in five (22%) advisors anticipates relying more on model portfolios in the next year, a five-percentage-point drop from 2022.
Concerns about underperformance and fees, combined with the need for customization and a more comprehensive array of fund options, are driving the stalling growth of model portfolios.
These are the latest findings from Cogent Syndicated’s Advisor Use of Model Portfolios and SMAs™ report, which tracks advisors’ use of model portfolios and SMAs, along with perceptions of leading model portfolio providers and SMA managers.

Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics

Retrieved on:

Tuesday, January 9, 2024

Patient, AAAAI, PEAK, American Academy, Initiate, Cancer, FGFR2, Q&A, Gene family, IND, Cogent, Conference, PRO, Finalize (optical discs), GIST, HER2, TSS, APEX, Pharmaceutical industry

ET

Key Points:

ET
WALTHAM, Mass.
and BOULDER, Colo., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today highlighted the company’s key 2024 milestones ahead of its presentation at J.P. Morgan’s 42nd annual healthcare conference.
“Given the foundation that was established in 2023, we are well positioned to move Cogent forward aggressively this year, including a cash runway expected to carry us into 2026,” said Andrew Robbins, President and CEO of Cogent Biosciences.
A live webcast will be accessible in the “Investors & Media” section of the company’s website, www.cogentbio.com , and will be archived for 30 days following the event.

Leading Utilities Increase Business Customer Engagement by Offering Reliable Energy Partnerships

Retrieved on:

Tuesday, December 19, 2023

Cogent, Intensity, Haggerty, Business, Research, Customer, Behavior, Energy, Communication, Index, ECR, Retail

Despite the trending decline, 17 outstanding utilities, recognized today as Escalent’s 2023 Business Customer Champions, have scored well above their industry peers for building engaged customer relationships.

Key Points:

Despite the trending decline, 17 outstanding utilities, recognized today as Escalent’s 2023 Business Customer Champions, have scored well above their industry peers for building engaged customer relationships.
Business Customer Champions are offering a valuable array of opt-in programs with low-effort enrollment processes, leading to 6% higher Product Benefits Awareness Index scores.
“In tough economic times, affordability, transparency and community connections are key to business customer engagement,” Haggerty continued.
“Utilities that prove their value as a vital part of the local economic community and act as a trusted energy advisor for their business customers will pave the way to better relationships.”
Escalent is pleased to name these 17 utilities as our 2023 Business Customer Champions.

Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)

Retrieved on:

Saturday, December 9, 2023

Twenty patients in Part 1a were treated with either bezuclastinib or placebo plus best supportive care for all arms.

Key Points:

Twenty patients in Part 1a were treated with either bezuclastinib or placebo plus best supportive care for all arms.
Patients were enrolled with the following sub-types: 18 patients with indolent systemic mastocytosis (ISM) and two patients with smoldering systemic mastocytosis (SSM).
In patients with completed questionnaires:
By week 12, bezuclastinib patients showed a median best improvement of 37% on MC-QoL vs. 24% for placebo patients.
Data from Part 1 of the Phase 2 APEX clinical trial evaluating bezuclastinib in patients with advanced systemic mastocytosis (AdvSM) will be presented in a poster session at ASH on Monday, December 11, 2023 at ASH.